KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Current Oncology · 03.04.2024 · 31 (4) · 2024-2046
DOI: 10.3390/curroncol31040150 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 03.04.2024. Verfasst von Leonard J Ash und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Hunter College, City University of New York, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Neoplasms. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Hunter College of the City University of New York.
Abstract (Originalsprache)
KRAS is a small GTPase that is among the most commonly mutated oncogenes in cancer. Here, we discuss KRAS biology, therapeutic avenues to target it, and mechanisms of resistance that tumors employ in response to KRAS inhibition. Several strategies are under investigation for inhibiting oncogenic KRAS, including small molecule compounds targeting specific KRAS mutations, pan-KRAS inhibitors, PROTACs, siRNAs, PNAs, and mutant KRAS-specific immunostimulatory strategies. A central challenge to therapeutic effectiveness is the frequent development of resistance to these treatments. Direct resistance mechanisms can involve KRAS mutations that reduce drug efficacy or copy number alterations that increase the expression of mutant KRAS. Indirect resistance mechanisms arise from mutations that can rescue mutant KRAS-dependent cells either by reactivating the same signaling or via alternative pathways. Further, non-mutational forms of resistance can take the form of epigenetic marks, transcriptional reprogramming, or alterations within the tumor microenvironment. As the possible strategies to inhibit KRAS expand, understanding the nuances of resistance mechanisms is paramount to the development of both enhanced therapeutics and innovative drug combinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Hunter College, City University of New York, New York, NY 10065, USA.
- Molecular, Cellular, and Developmental Biology Subprogram of the Biology Ph.D. Program, Graduate Center, City University of New York, New York, NY 10031, USA.
- Biochemistry Ph.D. Program, Graduate Center, City University of New York, New York, NY 10031, USA.
- Macaulay Honors College, Hunter College, City University of New York, New York, NY 10065, USA.
- Department of Pharmacology, Weill Cornell Medicine, New York, NY 10021, USA.
ORCID-Profile: Leonard J Ash, Ottavia Busia-Bourdain, Daniel Okpattah
Förderung
- NCI NIH HHS
- National Cancer Institute
- Hunter College of the City University of New York
- Oncogenuity, Inc.
- Damon Runyon Cancer Research Foundation
- Graduate Center of the City University of New York
Zitieren
APA
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024). KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance. Current Oncology, 31(4), 2024-2046. https://doi.org/10.3390/curroncol31040150
Vancouver
Ash LJ, Busia-Bourdain O, Okpattah D, Kamel A, Liberchuk A, Wolfe AL. KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance. Current Oncology. 2024;31(4):2024-2046. doi:10.3390/curroncol31040150
BibTeX
@article{Ash2024,
author = {Ash, Leonard J and Busia-Bourdain, Ottavia and Okpattah, Daniel and Kamel, Avrosina and Liberchuk, Ariel and Wolfe, Andrew L},
title = {KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance},
journal = {Current Oncology},
year = {2024},
volume = {31},
number = {4},
pages = {2024--2046},
doi = {10.3390/curroncol31040150}
}
EUVIMED